Why the study?
Does TIMP3 deficiency accelerate tumor invasion and increase prostate inflammation in a mouse model of prostate cancer?
Does TIMP3 deficiency accelerate tumor invasion and increase prostate inflammation in a mouse model of prostate cancer?
TIMP3 loss promotes prostate cancer invasion and inflammation in a Pten-deficient mouse model, highlighting the role of altered protease activity in cancer progression.
No takes yet. Share an insight, caveat, or question.
No immediate clinical implications for prostate cancer; leaves open TIMP3 as a therapeutic target pending human studies.
Adissu et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: